Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
0

Story being shared
Xarelto gains expanded indication from the FDA
The FDA approved expanded use of Johnson & Johnson's blood thinner Xarelto to treat and reduce patients' risk of deep vein thrombosis and pulmonary embolism recurrence.

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .